Want to join the conversation?
$VRTX and Moderna Therapeutics said they have entered into exclusive research collaboration and licensing agreement aimed at the discovery and development of messenger Ribonucleic Acid (mRNA) Therapeutics for treatment of cystic fibrosis (CF). Through collaboration, companies will explore potential utilization of pulmonary mRNA delivery.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.